Technical Analysis for AERI - Aerie Pharmaceuticals, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Flat | Down |
| See historical AERI trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Mar 26 | 50 DMA Support | Bullish | 0.00% |
| Mar 26 | Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% |
| Mar 26 | Bollinger Band Squeeze | Range Contraction | 0.00% |
| Mar 26 | BB Squeeze + Lower Band Touch | Range Contraction | 0.00% |
| Mar 26 | Down 3 Days in a Row | Weakness | 0.00% |
| Mar 26 | Lower Bollinger Band Touch | Weakness | 0.00% |
| Mar 25 | Fell Below 20 DMA | Bearish | -1.60% |
| Mar 25 | Bollinger Band Squeeze | Range Contraction | -1.60% |
| Mar 25 | BB Squeeze + Lower Band Touch | Range Contraction | -1.60% |
| Mar 25 | Lower Bollinger Band Touch | Weakness | -1.60% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-02-25
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Its product candidates include dual-action AR-13324, a once-daily eye drop to reduce intraocular pressure (IOP) in patients with glaucoma or ocular hypertension, which has completed a Phase IIb clinical trials; triple-action PG324, a single drop fixed-dose combination of AR-13324 and latanoprost for the treatment of patients with glaucoma; and AR-13533, a dual-action ROCK/NET inhibitor that is in preclinical development stage. The company was founded in 2005 and is headquartered in Bedminster, New Jersey.
Chemistry Pharmaceutical Diseases Chemical Compounds Organic Compounds Glaucoma Alcohols Cyclopropanes Aerie Pharmaceuticals Intraocular Pressure Ocular Hypertension Prostaglandins
Chemistry Pharmaceutical Diseases Chemical Compounds Organic Compounds Glaucoma Alcohols Cyclopropanes Aerie Pharmaceuticals Intraocular Pressure Ocular Hypertension Prostaglandins
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more AERI news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 74.75 |
| 52 Week Low | 32.18 |
| Average Volume | 724,646 |
| 200-Day Moving Average | 53.0369 |
| 50-Day Moving Average | 44.651 |
| 20-Day Moving Average | 46.7225 |
| 10-Day Moving Average | 46.741 |
| Average True Range | 2.3805 |
| ADX | 24.53 |
| +DI | 25.1212 |
| -DI | 20.1364 |
| Chandelier Exit (Long, 3 ATRs ) | 42.9585 |
| Chandelier Exit (Short, 3 ATRs ) | 46.6415 |
| Upper Bollinger Band | 48.7745 |
| Lower Bollinger Band | 44.6705 |
| Percent B (%b) | 0.03 |
| BandWidth | 8.783777 |
| MACD Line | 0.6291 |
| MACD Signal Line | 0.9244 |
| MACD Histogram | -0.2953 |
| Fundamentals | Value |
|---|---|
| Market Cap | 1.63 Billion |
| Num Shares | 36.3 Million |
| EPS | -3.26 |
| Price-to-Earnings (P/E) Ratio | -13.74 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 12.18 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 48.47 | ||||
| Resistance 3 (R3) | 48.49 | 47.28 | 47.86 | ||
| Resistance 2 (R2) | 47.28 | 46.34 | 47.27 | 47.65 | |
| Resistance 1 (R1) | 46.03 | 45.75 | 45.42 | 46.01 | 47.45 |
| Pivot Point | 44.81 | 44.81 | 44.51 | 44.81 | 44.81 |
| Support 1 (S1) | 43.57 | 43.87 | 42.96 | 43.55 | 42.11 |
| Support 2 (S2) | 42.35 | 43.29 | 42.34 | 41.91 | |
| Support 3 (S3) | 41.10 | 42.35 | 41.70 | ||
| Support 4 (S4) | 41.09 |
